Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.

89th Legislature, 2nd Called Session (2025) Introduced by Daniel Alders and 70 co-sponsors

Texas bans abortion-inducing drug manufacture and provision while authorizing citizen lawsuits against violators and shielding Texas actors from other states' conflicting laws.

Effective on . . . . . . . . . . . . . . .

#abortion(i0005) #civilremedies&liabilities(i0065) #courts--general(i0160) #fifteenthcourtofappeals(vm34v) #healthcareproviders(i0387) #medicine&prescriptiondrugs(s7338) #physicians(s1282) #pregnancy&childbirth(s0294) #woman&childprotectionact(p26oy)

Legislative bill overview

HB 7 prohibits the manufacture and provision of abortion-inducing drugs (primarily mifepristone and misoprostol) within Texas and extends enforcement to target suppliers outside the state. The bill authorizes private citizens to bring lawsuits (qui tam actions) against anyone who violates these prohibitions and provides legal protections for Texas residents and entities from out-of-state laws that might compel them to provide these drugs.

Why is this important

This legislation significantly restricts access to medication abortion in Texas and attempts to prevent out-of-state suppliers from providing these drugs to Texas residents. It creates a private enforcement mechanism that could result in substantial financial liability for violators, making it one of the nation's most restrictive abortion access laws and establishing a model that may influence other states.

Potential points of contention

Constitutional challenges: Federal courts have previously blocked similar restrictions on mifepristone based on FDA approval and interstate commerce grounds; this law will likely face immediate legal challenges

Enforcement mechanisms: Qui tam provisions may incentivize lawsuits against healthcare providers, pharmacies, and individuals, raising concerns about frivolous litigation and chilling lawful conduct

Interstate commerce conflicts: Provisions targeting out-of-state suppliers and protecting Texas entities from other states' laws create potential conflicts with constitutional commerce clause protections and existing multi-state legal frameworks

Practical impact on healthcare: May restrict legitimate medical care and create confusion among healthcare providers about permissible treatment options